Group 1 - The core viewpoint of the news highlights the strong momentum in China's innovative drug licensing transactions, with 44 license-out deals reported in 2026, totaling approximately $53.28 billion, including an upfront payment of about $3.12 billion [1] - The China Innovation Drug Business Development (BD) is undergoing three major transformations: technology output with joint product licensing, platform cooperation, and global parallel innovation [2] - The China Medical and Medical Device Innovation Index (931484) includes 30 companies with strong profitability and growth potential, reflecting the overall performance of profitable and innovative pharmaceutical and medical device companies [2] Group 2 - The top ten weighted stocks in the China Medical and Medical Device Innovation Index as of January 30, 2026, include WuXi AppTec, Mindray Medical, and Heng Rui Medicine, accounting for 63.9% of the index [2] - The Medical Innovation ETF (516820) has seen a continuous net inflow of funds over the past three days, with a maximum single-day net inflow of 6.17 million yuan, totaling 12.70 million yuan [1]
中国创新药年内海外授权总金额突破530亿美元，医疗创新ETF(516820)连续3天净流入
Xin Lang Cai Jing·2026-02-26 02:14